A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects

NCT01738555 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus Infection

Interventions

DRUG: amdoxovir 300 mg bid
DRUG: amdoxovir 500 mg bid

Sponsor

RFS Pharma, LLC